Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 7;31(10):617.
doi: 10.1007/s00520-023-08101-x.

Dose-limiting mucositis: friend or foe?

Clifton P Thornton  1   2 , Etan Orgel  3   4
Affiliations

Dose-limiting mucositis: friend or foe?

Clifton P Thornton et al. Support Care Cancer. .

Abstract

Dose-limiting toxicities are ubiquitous to cancer-directed therapy, presenting with severity to a degree that necessitates therapy de-escalation, pause, or discontinuation. To date, there is incredible limited understanding if these therapy de-escalations present risk for survival by limiting delivery of intensive therapy, or if they indicate physiologic susceptibility and are a favorable prognostic indicator. Mucositis is an excellent illustration of the current paradox of dose-limiting toxicities-it has existed alongside therapy for eight decades, but despite its presence, there is an incomplete understanding of how it develops, why it varies between oncologic populations, and if it relates to cancer survival. Rigorous methodologic approaches in symptom science holds potential to better understand mucositis, to determine if it is a marker of response or threat, and evaluate if it holds potential to guide therapy delivery.

Keywords: Dose-limiting toxicities; Mucositis; Pediatric oncology; Therapy de-escalations.

PubMed Disclaimer

References

    1. Collins M, Wilhelm M, Conyers R et al (2013) Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 31(18):2303–2312. https://doi.org/10.1200/jco.2012.43.8598 - DOI - PubMed
    1. Fanning SR, Rybicki L, Kalaycio M et al (2006) Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 135(3):374–381. https://doi.org/10.1111/j.1365-2141.2006.06323.x - DOI - PubMed
    1. Nageswara Rao AA, Wallace DJ, Billups C, Boyett JM, Gajjar A, Packer RJ (2014) Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children’s Oncology Group. Pediatr Blood Cancer 61(1):102–106. https://doi.org/10.1002/pbc.24670 - DOI - PubMed
    1. McTiernan A, Jinks RC, Sydes MR et al (2012) Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer 48(5):703–712. https://doi.org/10.1016/j.ejca.2011.09.012 - DOI - PubMed - PMC
    1. Wong HH, Halford S (2015) Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol 16(13):1287–1288. https://doi.org/10.1016/S1470-2045(15)00248-X - DOI - PubMed

LinkOut - more resources